Curanex Pharmaceuticals Inc
CURX · XNASCIK 2025942fmd_1DR9MTCVX9AWEEQGVZRT28XW79Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2024 to Sep 30, 2026, 11 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Research and development | – | 3 |
| Total operating expenses | 0 | 4 |
| Operating income | (0) | (4) |
| Interest expense | – | 0 |
| Net income | (0) | (4) |